Updated Clinical Practice Guidelines on Heart Failure: An International Alignment
2016; Lippincott Williams & Wilkins; Volume: 134; Issue: 13 Linguagem: Inglês
10.1161/cir.0000000000000436
ISSN1524-4539
AutoresElliott M. Antman, Jeroen J. Bax, Richard A. Chazal, Mark A. Creager, Gerasimos Filippatos, Jonathan L. Halperin, Steven R. Houser, JoAnn Lindenfeld, Fausto J. Pinto, Panos Vardas, Mary Norine Walsh, Kim A. Williams, José Luis Zamorano,
Tópico(s)Cardiac pacing and defibrillation studies
ResumoHomeCirculationVol. 134, No. 13Updated Clinical Practice Guidelines on Heart Failure: An International Alignment Free AccessResearch ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessResearch ArticlePDF/EPUBUpdated Clinical Practice Guidelines on Heart Failure: An International Alignment Elliott M. Antman, MD, Jeroen Bax, MD, Richard A. Chazal, MD, Mark A. Creager, MD, Gerasimos Filippatos, MD, Jonathan L. Halperin, MD, Steven Houser, MD, JoAnn Lindenfeld, MD, Fausto J. Pinto, MD, Panos Vardas, MD, Mary Norine Walsh, MD, Kim A. WilliamsSr, MD and Jose L. Zamorano, MD Elliott M. AntmanElliott M. Antman , Jeroen BaxJeroen Bax , Richard A. ChazalRichard A. Chazal , Mark A. CreagerMark A. Creager , Gerasimos FilippatosGerasimos Filippatos , Jonathan L. HalperinJonathan L. Halperin , Steven HouserSteven Houser , JoAnn LindenfeldJoAnn Lindenfeld , Fausto J. PintoFausto J. Pinto , Panos VardasPanos Vardas , Mary Norine WalshMary Norine Walsh , Kim A. WilliamsSrKim A. WilliamsSr and Jose L. ZamoranoJose L. Zamorano Originally published20 May 2016https://doi.org/10.1161/CIR.0000000000000436Circulation. 2016;134:e280–e281Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: January 1, 2016: Previous Version 1 IntroductionThe American College of Cardiology (ACC), the American Heart Association (AHA), and the European Society of Cardiology (ESC) are pleased to announce the publication of 2 updated clinical practice guidelines on management of patients with heart failure, which have been produced in collaboration with the Heart Failure Society of America (HFSA) and the Heart Failure Association (HFA) of the ESC.The introduction of an angiotensin receptor-neprilysin inhibitor (ARNI), valsartan/sacubitril, and a sinoatrial node modulator, ivabradine, when applied judiciously, complement established pharmacological and device-based therapies, representing milestones in the evolution of care for patients with heart failure. Accordingly, the writing committees of the "ESC 2016 Guideline on the Diagnosis and Treatment of Acute and Chronic Heart Failure Developed With the Special Contribution of the HFA"1 and the "2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure"2 concurrently developed recommendations for the incorporation of these therapies into clinical practice. The ESC guideline is a complete revision of the "ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure (2012) Developed With the Special Contribution of the HFA."3 The ACC/AHA/HFSA document, developed in partnership with the HFSA, is part of a Focused Update of the "2013 ACCF/AHA Guideline for the Management of Heart Failure"4 that will be published within the next year.Each writing committee surveyed the evidence independently and constructed similar recommendations, which were then shared between the organizations. Given the robust processes used by both expert writing committees to review the evidence and develop these recommendations and the concordance between them, the organizations agreed to publish them concurrently to unify the message, minimize confusion, and improve and standardize the care of patients with heart failure.The officers of the ACC, AHA, and ESC and their respective guideline oversight committees meet regularly to discuss opportunities for coordination and alignment on overlapping topics and evolution of the methodology used to gather and evaluate scientific evidence. The objective is to promote optimal care for patients with all forms of cardiovascular disease to improve outcomes and enhance quality of life around the world. The new documents represent an important step in this direction.FootnotesThe American Heart Association requests that this document be cited as follows: Antman EM, Bax J, Chazal RA, Creager MA, Filippatos G, Halperin JL, Houser S, Lindenfeld J, Pinto FJ, Vardas P, Walsh MN, Williams KA Sr, Zamorano JL. Updated clinical practice guidelines on heart failure: an international alignment. Circulation. 2016;134:e280–e281. DOI: 10.1161/CIR.0000000000000436.This article has been copublished in the Journal of the American College of Cardiology, Journal of Cardiac Failure, European Journal of Heart Failure, and the European Heart Journal.Copies: This document is available on the websites of the American College of Cardiology (www.acc.org), the American Heart Association (professional.heart.org), the Heart Failure Society of America (www.hfsa.org), and the European Society of Cardiology (www.escardio.org/guidelines). To purchase additional reprints, call 843-216-2533 or e-mail [email protected].Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at http://www.heart.org/HEARTORG/General/Copyright-Permission-Guidelines_UCM_300404_Article.jsp. A link to the "Copyright Permissions Request Form" appears on the right side of the page.Circulation is available at http://circ.ahajournals.org.References1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC [published online ahead of print May 20, 2016].Eur Heart J. DOI: 10.1093/eurheartj/ehw128 ehw128. http://dx.doi.org/10.1093/eurheartj/ehw128ehw128. Accessed June 29, 2016.Google Scholar2. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.Circulation. 2016; 135:e282–e293. doi: 10.1161/CIR.0000000000000435.Google Scholar3. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology.Eur Heart J. 2012; 33:1787–847.CrossrefMedlineGoogle Scholar4. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Circulation. 2013; 128:e240–327. doi: 10.1161/CIR.0b013e31829e8776.LinkGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited ByPavlović J, Greenland P, Franco O, Kavousi M, Ikram M, Deckers J, Ikram M and Leening M (2021) Recommendations and Associated Levels of Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: A Comparison at Population Level of the American Heart Association/American College of Cardiology/Multisociety, US Preventive Services Task Force, Department of Veterans Affairs/Department of Defense, Canadian Cardiovascular Society, and European Society of Cardiology/European Atherosclerosis Society Clinical Practice Guidelines, Circulation: Cardiovascular Quality and Outcomes, 14:9, (e007183), Online publication date: 1-Sep-2021. Kadam U, Roberts I, White S, Bednall R, Khunti K, Nilsson P and Lawson C (2019) Conceptualizing multiple drug use in patients with comorbidity and multimorbidity: proposal for standard definitions beyond the term polypharmacy, Journal of Clinical Epidemiology, 10.1016/j.jclinepi.2018.10.014, 106, (98-107), Online publication date: 1-Feb-2019. Stavropoulos K, Imprialos K and Doumas M (2017) Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension, The Journal of Clinical Hypertension, 10.1111/jch.13146, 20:1, (65-68), Online publication date: 1-Jan-2018. Cautela J, Lalevée N, Ammar C, Ederhy S, Peyrol M, Debourdeau P, Serin D, Le Dolley Y, Michel N, Orabona M, Barraud J, Laine M, Bonello L, Paganelli F, Barlési F and Thuny F (2016) Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspectives, International Journal of Cardiology, 10.1016/j.ijcard.2016.09.046, 224, (366-375), Online publication date: 1-Dec-2016. September 27, 2016Vol 134, Issue 13 Advertisement Article InformationMetrics © 2016 by the American Heart Association, Inc., the American College of Cardiology Foundation, the Heart Failure Society of America, and the Heart Failure Association and the European Society of Cardiology.https://doi.org/10.1161/CIR.0000000000000436PMID: 27208049 Originally publishedMay 20, 2016 KeywordsAHA Scientific Statementsheart failurePDF download Advertisement SubjectsStatements and Guidelines
Referência(s)